Press Releases

PTC is committed to serving the interests of all our stakeholders.
Pam & Kelsey
Living with PKU, United States

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Nov 06, 2014
PTC Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
- Confirmatory Phase 3 ACT DMD clinical trial fully enrolled -
- Rolling NDA submission for Translarna in nmDMD planned before year end 2014 -
- European commercial launch activities well underway -
- Initiation of Phase 1b/2a trial for SMA program planned -
- IND application for PTC596 to be submitted before year end 2014 -
- Successful financing raised estimated net proceeds of $117.5 million -
Read More
Oct 09, 2014
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH PLAINFIELD, N.J. , Oct. 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the
Read More
Oct 08, 2014
PTC Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH PLAINFIELD, N.J. , Oct. 8, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it is commencing an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed
Read More